Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
2.900
-0.200 (-6.45%)
At close: Jun 27, 2025, 4:00 PM
2.920
+0.020 (0.69%)
After-hours: Jun 27, 2025, 7:58 PM EDT
Company Description
Medicus Pharma Ltd., a biotech/life sciences company, focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets.
It develops SkinJect, with an indication for basal cell carcinoma that is drug device combination product using novel dissolvable microneedle arrays for the treatment of non-melanoma skin cancers.
The company was founded in 2015 and is headquartered in Toronto, Canada.
Medicus Pharma Ltd.
| Country | Canada |
| Founded | 2008 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| CEO | Raza Bokhari |
Contact Details
Address: One First Canadian Place, Suite 3400 Toronto, ON M5X 1A4 Canada | |
| Website | medicuspharma.com |
Stock Details
| Ticker Symbol | MDCX |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001997296 |
| ISIN Number | CA58471K2020 |
| Employer ID | 98-1778211 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raza Bokhari M.B.A., M.D., MBA | Chief Executive Officer and Executive Chairman |
| Dr. Edward J. Brennan Jr., F.A.C.S., FACS, M.D. | Chief Scientific Officer and Head of Research & Development Program |
| Carolyn Bonner | President |
| Anna Baran-Djokovic J.D. | Senior Vice President of Investor Relations |
| Viktoriia Slepeniuk | Senior Vice President of Public Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Jun 24, 2025 | 424B3 | Prospectus |
| Jun 24, 2025 | 424B3 | Prospectus |
| Jun 24, 2025 | 424B3 | Prospectus |
| Jun 23, 2025 | PRER14A | Filing |
| Jun 23, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 424B3 | Prospectus |
| Jun 20, 2025 | 424B3 | Prospectus |
| Jun 20, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Jun 20, 2025 | 424B3 | Prospectus |